Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms

被引:65
作者
Fujiwara, Ryoichi
Nakajima, Miki
Yamanaka, Hiroyuki
Nakamura, Akiko
Katoh, Miki
Ikushiro, Shin-ichi
Sakaki, Toshiyuki
Yokoi, Tsuyoshi [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Drug Metab & Toxicol, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
[2] Toyama Prefectural Univ, Biotechnol Res Ctr, Fac Engn, Toyama, Japan
关键词
D O I
10.1124/dmd.106.014191
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We established stable HEK293 cell lines expressing double isoforms, UGT1A1 and UGT1A9, UGT1A4 and UGT1A9, or UGT1A6 and UGT1A9, as well as stable cell lines expressing each single isoform. To analyze the protein-protein interaction between the UGT1As, we investigated the thermal stability and resistance to detergent. UGT1A9 uniquely demonstrated thermal stability, which was enhanced in the presence of UDP-glucuronic acid (>90% of control), and resistance to detergent. Interestingly, UGT1A1, UGT1A4, and UGT1A6 acquired thermal stability and resistance to detergent by the coexpression of UGT1A9. An immunoprecipitation assay revealed that UGT1A6 and UGT1A9 interact in the double expression system. Using the single expression systems, it was confirmed that estradiol 3-O-glucuronide, imipramine N-glucuronide, serotonin O-glucuronide, and propofol O-glucuronide formations are specific for UGT1A1, UGT1A4, UGT1A6, and UGT1A9, respectively. By kinetic analyses, we found that the coexpressed UGT1A9 significantly affected the kinetics of estradiol 3-O-glucuronide formation (decreased V-max), imipramine N-glucuronide formation (increased K-m and V-max), and serotonin O-glucuronide formation (decreased V-max) catalyzed by UGT1A1, UGT1A4, and UGT1A6, respectively. On the other hand, the coexpressed UGT1A1 increased Km and decreased the V-max of the propofol O-glucuronide formation catalyzed by UGT1A9. The coexpressed UGT1A4 and UGT1A6 also increased the V-max of the propofol O-glucuronide formation by UGT1A9. This is the first study showing that human UGT1A isoforms interact with other isoforms to change the enzymatic characteristics.
引用
收藏
页码:747 / 757
页数:11
相关论文
共 33 条
[1]  
[Anonymous], 1980, GLUCURONIDATION DRUG
[2]   SEQUENCE OF EXONS AND THE FLANKING REGIONS OF HUMAN BILIRUBIN-UDP-GLUCURONOSYLTRANSFERASE GENE-COMPLEX AND IDENTIFICATION OF A GENETIC MUTATION IN A PATIENT WITH CRIGLER-NAJJAR SYNDROME, TYPE-I [J].
BOSMA, PJ ;
CHOWDHURY, NR ;
GOLDHOORN, BG ;
HOFKER, MH ;
ELFERINK, RPJO ;
JANSEN, PLM ;
CHOWDHURY, JR .
HEPATOLOGY, 1992, 15 (05) :941-947
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
Fisher MB, 2000, DRUG METAB DISPOS, V28, P560
[5]   Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil) [J].
Ghosal, A ;
Hapangama, N ;
Yuan, Y ;
Achanfuo-Yeboah, J ;
Iannucci, R ;
Chowdhury, S ;
Alton, K ;
Patrick, JE ;
Zbaida, S .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (02) :267-271
[6]   RADIATION INACTIVATION ANALYSIS OF MICROSOMAL UDP-GLUCURONOSYLTRANSFERASES CATALYZING MONOGLUCURONIDE AND DIGLUCURONIDE FORMATION OF 3,6-DIHYDROXYBENZO(A)PYRENE AND 3,6-DIHYDROXYCHRYSENE [J].
GSCHAIDMEIER, H ;
BOCK, KW .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (08) :1545-1549
[7]  
Hawes EM, 1998, DRUG METAB DISPOS, V26, P830
[8]   Crystal structure of the MurG:UDP-GlcNAc complex reveals common structural principles of a superfamily of glycosyltransferases [J].
Hu, YN ;
Chen, L ;
Ha, S ;
Gross, B ;
Falcone, B ;
Walker, D ;
Mokhtarzadeh, M ;
Walker, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) :845-849
[9]   Protein-protein interactions between UDP-glucuronosyltransferase isozymes in rat hepatic microsomes [J].
Ikushiro, S ;
Emi, Y ;
Iyanagi, T .
BIOCHEMISTRY, 1997, 36 (23) :7154-7161
[10]   Monospecific antipeptide antibodies against human hepatic UDP-Glucuronosyltransferase]A subfamily (UGT1A) Isoforms [J].
Ikushiro, Shin-Ichi ;
Emi, Yoshikazu ;
Kato, Yoshihisa ;
Yamada, Shizuo ;
Sakaki, Toshiyuki .
DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (01) :70-74